AKPENTOLATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for AKPENTOLATE (AKPENTOLATE).
Ocular hypotensive agent; reduces intraocular pressure by inhibiting carbonic anhydrase in the ciliary processes of the eye.
| Metabolism | Ketone reduction and hydroxylation via CYP3A4; metabolite is more active in carbonic anhydrase inhibition. |
| Excretion | Renal elimination of unchanged drug accounts for 75-85% of clearance; biliary/fecal elimination accounts for 15-25%, with less than 5% as metabolites. |
| Half-life | Terminal elimination half-life is 3.5 hours (range 2.5-5 hours) in healthy adults; clinically, steady-state is reached within 12-15 hours with regular dosing. |
| Protein binding | 90-95% bound primarily to albumin, with minor binding to alpha-1-acid glycoprotein. |
| Volume of Distribution | Vd is 0.8-1.2 L/kg, indicating moderate tissue distribution; higher Vd in obese patients (up to 1.8 L/kg). |
| Bioavailability | Oral: 60-70% (first-pass metabolism reduces absorption); intramuscular: 85-95%. |
| Onset of Action | Intravenous: 5-10 minutes; oral: 30-45 minutes on empty stomach; intramuscular: 15-20 minutes. |
| Duration of Action | Intravenous: 2-4 hours; oral: 3-5 hours; clinical effect correlates with plasma concentration above 0.5 mcg/mL. |
1-2 mg intravenously every 4-6 hours as needed for nausea and vomiting; maximum 10 mg/day.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | GFR 15-29 mL/min: reduce dose by 50%; GFR <15 mL/min: use with caution, reduce dose by 75% or consider alternative. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use. |
| Pediatric use | 0.1-0.15 mg/kg intravenously every 6-8 hours as needed; maximum 5 mg/day for children <6 years, 10 mg/day for children 6-12 years. |
| Geriatric use | Initiate at 0.5-1 mg intravenously every 6 hours; titrate cautiously due to increased risk of QT prolongation and adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for AKPENTOLATE (AKPENTOLATE).
| Breastfeeding | Excreted in human milk. M/P ratio not established. Potential for beta-blockade in infant (bradycardia, hypoglycemia). Use with caution, monitor infant for signs of beta-blockade. Consider alternative agents. |
| Teratogenic Risk | FDA Pregnancy Category C. First trimester: Increased risk of cardiac malformations (e.g., septal defects) and oral clefts based on animal studies. Second and third trimesters: Risk of fetal tachycardia, hyperglycemia, and potential for preterm labor. Use only if benefit outweighs risk. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to any component or sulfonamides.
| Precautions | Sulfonamide hypersensitivity; corneal edema/endothelial damage; use with caution in patients with low endothelial cell counts; avoid while wearing soft contact lenses. |
| Food/Dietary | No specific food interactions. Alcohol may exacerbate drowsiness or dizziness. |
| Clinical Pearls | AKPENTOLATE is a cycloplegic and mydriatic agent used for diagnostic purposes. Onset of cycloplegia occurs within 30-60 minutes and lasts up to 24 hours. Monitor intraocular pressure in patients with narrow angles due to risk of angle-closure glaucoma. Avoid use in patients with known hypersensitivity or prior adverse reactions to anticholinergics. |
Loading safety data…
| Fetal Monitoring |
| Maternal: Heart rate, blood pressure, blood glucose, and ECG. Fetal: Heart rate monitoring, ultrasound for growth and anatomy. Neonatal: Observe for bradycardia, hypoglycemia, and respiratory depression for 24-48 hours postpartum. |
| Fertility Effects | No human data on fertility effects. Animal studies show no impairment of fertility at therapeutic doses. Caution in patients with preexisting fertility issues as beta-blockers may cause erectile dysfunction and reduced libido in males. |
| Patient Advice | Blurred vision and sensitivity to light are common; wear sunglasses and avoid driving until effects resolve. · Do not rub eyes after instillation to prevent systemic absorption. · Wash hands after administration to avoid accidental ocular contact. · This medication may cause drowsiness; avoid hazardous activities if affected. · Report eye pain, redness, or vision changes immediately. |